No interference by diclofenac with the new vitros FT311 assay reagent [4]

Clinical Chemistry

Volumn 50, Issue 11, 2004, Pages 2218-2219

  Iwahara, Kunihiro ^a   Tanabe, Chizuko ^a   Maekawa, Masato ^a  

^a HAMAMATSU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

DICLOFENAC; LIOTHYRONINE; NONSTEROID ANTIINFLAMMATORY AGENT; PHENYLACETIC ACID DERIVATIVE; THYROXINE;

ANALYTICAL EQUIPMENT; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG CROSS REACTIVITY; FREE LIOTHYRONINE INDEX; FREE THYROXINE INDEX; HUMAN; HUMAN TISSUE; HYPOTHYROIDISM; LETTER; REFERENCE VALUE; STATISTICAL ANALYSIS; THYROID DISEASE; THYROID FUNCTION TEST; THYROTROPIN BLOOD LEVEL;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CROSS REACTIONS; DICLOFENAC; HUMANS; IMMUNOASSAY; REAGENT KITS, DIAGNOSTIC; THYROID FUNCTION TESTS; TRIIODOTHYRONINE;

EID: 7044235669     PISSN: 00099147     EISSN: None     Source Type: Journal    
DOI: 10.1373/clinchem.2004.041988     Document Type: Letter

References (6)

1. Isaacs AJ, Monk BE. Fenclofenac interferes with thyroid-function tests. Lancet 1980;1:267-8.
2. Bartha KG. Iodine kinetics of the organism under the influence of phenylbutazone. Acta Med Acad Sci Hung 1971;28:271-7.
3. Tillman J, Leask JT, Campbell J, Logue FC, Fraser WD. Effect of fenoprofen on thyroid function tests. Clin Chim Acta 1986;161:233-8.
4. Kasono K, Hikino H, Fujino S, Takemoto N, Kai T, Yamaguchi K, et. al. Cross-reactive mechanism for the false elevation of free triiodothyronine in the patients treated with diclofenac. Endocr J 2001;48:717-22.
5. National Committee for Clinical Laboratory Standards. Performance of clinical chemistry devices, 2nd ed.; tentative guideline. NCCLS Document EP5-T2. Wayne, PA: NCCLS, 1992.
6. Garcia M, Calzada-Leon R, Perez J, Martinez MP, Gonzalez R, Perez M, et al. Longitudinal assessment of L-T4 therapy for congenital hypothyroidism: differences between athyreosis vs ectopia and delayed vs normal bone age. J Pediatr Endocrinol Metab 2000;13:63-9.